Oncogenic mutations of PIK3CA in human cancers.

By Yardena Samuels, T. Waldman. Current Topics in Microbiology and Immunology, 2004

661 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cd7458e5fdda249fa0ae379cb3eadbaf4e01d872

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Arne Traulsen
2. Martin A. Nowak
3. Niko Beerenwinkel
4. Bert Vogelstein
5. J. Engelman
6. Giovanni Parmigiani
7. David G. Rand
8. Matjaz Perc

In Molecular Biology

1. Victor E. Velculescu
2. Bert Vogelstein
3. Kenneth W. Kinzler
4. K. Courtney
5. Niko Beerenwinkel
6. Martin A. Nowak
7. Arne Traulsen
8. R. Corcoran

In Pulmonary and Respiratory Medicine

1. J. Engelman

Citations in the corpus

• The PI3K pathway as drug target in human cancer. (2010, background): “Similarly, glioblastomas frequently exhibit PI3K activation, either through integration of signaling from multiple activated RTKs, such as the constitutively active EGFRvIII mutant, or through the combined activation of RTKs and loss of PTEN.71,72 The small GTPase Ras is also frequently mutated in h”
• Comparative lesion sequencing provides insights into tumor evolution (2008, background): “[6] If the average Tpot during mutation accumulation in both cells is identical, then Eq.”